Excretion of Loratadine in Human Breast Milk
- 1 March 1988
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 28 (3) , 234-239
- https://doi.org/10.1002/j.1552-4604.1988.tb03138.x
Abstract
The excretion of loratadine, a new nonsedating antihistamine, into human breast milk was studied in six lactating nonpregnant volunteers. Each volunteer received one 40-mg loratadine capsule. Milk and blood were collected before and at specified times (to 48 hours) after dosing. Plasma and milk loratadine concentrations were determined by a specific radioimmunoassay, and those of an active but minor metabolite, descarboethoxyloratadine, by high performance liquid chromatography (HPLC). Breast milk concentration-time curves of both loratadine and descarboethoxyloratadine paralleled the plasma concentration-time curves. For loratadine, the plasma Cmax was 30.5 ng/mL at 1.0 hour after dosing and the milk Cmax was 29.2 ng/mL in the 0 to 2 hour collection interval. Through 48 hours, the loratadine milk-plasma AUC ratio was 1.2 and 4.2 μg of loratadine was excreted in breast milk, which was 0.010% of the administered dose. For descarboethoxyloratadine, the plasma Cmax was 18.6 ng/mL at 2.2 hours after dosing, whereas the milk Cmax was 16.0 ng/mL, which was in the 4 to 8-hour collection interval. Through 48 hours, the mean milk-plasma descarboethoxyloratadine AUC ratio was 0.8 and a mean of 6.0 μg of descarboethoxyloratadine (7.5 μg loratadine equivalents) were excreted in the breast milk, or 0.019% of the administered loratadine dose. Thus, a total of 11.7 μg loratadine equivalents or 0.029% of the administered dose were excreted as loratadine and its active metabolite. A 4-kg infant ingesting the loratadine and descarboethoxyloratadine excreted would receive a dose equivalent to 0.46% of the loratadine dose received by the mother on a mg/kg basis. An estimated “worst-case” dose (i.e., the maximum dose that could be expected under any circumstances) of loratadine and descarboethoxyloratadine to an infant was calculated to be only 1.1% of the adult loratadine dose on a mg/kg basis. The adult dose has been reported to be safe and well tolerated, so it is unlikely that this dose presents a hazard to infants.This publication has 15 references indexed in Scilit:
- Pharmacokinetics and Dose Proportionality of LoratadineThe Journal of Clinical Pharmacology, 1987
- Loratadine: Multiple‐Dose PharmacokineticsThe Journal of Clinical Pharmacology, 1987
- Antiallergic activity of loratadine, a non‐sedating antihistamineAllergy, 1986
- Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serumAmerican Journal of Psychiatry, 1986
- Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine, a non-sedating antihistamineEuropean Journal of Pharmacology, 1986
- Pharmacologic evaluation of loratadine (SCH 29851), chlorpheniramine and placeboEuropean Journal of Clinical Pharmacology, 1986
- Excretion of doxepin and N‐desmethyldoxepin in human milk.British Journal of Clinical Pharmacology, 1985
- Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamineInflammation Research, 1984
- Determinants and Consequences of Drug Excretion in Breast MilkDrug Metabolism Reviews, 1983
- Drug Excretion in Human Breast Milk1,2Clinical Pharmacokinetics, 1980